Introduction
Vascular remodelling processes are characterized by considerable functional changes of cells in the entire vessel wall. Excessive proliferation of resident smooth muscle cells (SMC) has been established as one of the pathophysiological hallmarks in the process of neointima formation. 1 For a detailed understanding of the underlying pathomechanisms, little attention has been drawn so far to the adventitia, which was mostly referred to as a connective tissue layer with minor (patho)-physiological functions. In adventitial niches, mesenchymal stem cells (MSC) expressing stem cell antigen (Sca)-1 represent vascular progenitor cells, which were shown to have the potential to differentiate into SMC-like cells in vitro, a process critically dependent on Sonic hedgehog (Shh) signalling. 2 Moreover, myofibroblasts have been suggested to accumulate in the adventitia following vascular injury, to subsequently proliferate, and to some extent migrate toward the lumen, 3 but the final contribution of these cells has been scarcely investigated so far. Interestingly, Shh has been implicated in the functional regulation of fibroblasts in different contexts, e.g. by promoting fibroblast migration. 4 The Shh signal transduction cascade is crucial for the development of most tissues and organs as well as for vasculogenesis. 5 Binding of Shh to the transmembrane receptor patched-1 (PTCH1) interrupts the inhibitory effect of PTCH1 on the transmembrane protein smoothened (SMO), which results in activation of Gli transcription factors (Gli1-3). 6 In addition to this so-called 'canonical' pathway, recent evidence points toward two distinct classes of 'non-canonical' Shh signalling, which are independent of Gli-mediated transcription. Type I requires Shh ligand binding and is mediated through PTCH1-interaction with molecules of other pathways (e.g. cyclin B1 and caspases) unrelated to SMO repression, whereas Type II is dependent on SMO signalling. 7 In addition to Shh ligand binding, several other factors are decisive for Shh-signalling activity. For instance, SMO accumulation in the plasma membrane has been shown to be associated with enhanced signalling activity. 8 Even though the detailed molecular function of SMO is not fully understood, the SMO-inhibitor GDC-0449 (Vismodegib) reveals promising results in the treatment of numerous proliferative diseases such as basal cell carcinoma and represents the first Shh pathway inhibitor that lately gained approval by the FDA as well as the European Medicine Agency. 9 In this study, we investigated the impact of the adventitia on neointima formation and found that early activation of adventitial fibroblasts by SMO-dependent Shh signalling stimulated their proliferation and induced a robust expansion of the adventitial layer. These activated fibroblasts release pro-inflammatory cytokines and growth factors, thereby promoting the inflammatory response and the subsequent proliferation of SMC, which results in neointima formation. The specific SMO-inhibitor GDC-0449 selectively inhibited the activation of fibroblasts but not MSC or SMC. Mechanistically, we found that platelet-derived growth factor (PDGF)-BB cell-specifically induced the translocation of SMO to the plasma membrane in fibroblasts only and thus selectively rendered fibroblasts susceptible to SMO-dependent Shh inhibition. Importantly, perivascular application of GDC-0449 following wire-mediated vascular injury not only selectively prevented the proliferation and paracrine activation of adventitial fibroblasts but also significantly inhibited neointima formation and luminal stenosis.
Methods
For a detailed material and methods section, see Supplementary material online.
Cell culture
Human coronary artery smooth muscle cells, human coronary artery endothelial cells, and human aortic adventitial fibroblasts were purchased from Lonza (Cologne, Germany).
þ mouse mesenchymal stem cells were from LifeTechnologies (Carlsbad, CA, USA). CD45 þ cells were isolated from healthy human peripheral blood samples using the MACS MicroBeads technology (130-045-801, Miltenyi Biotec, Bergisch Gladbach, Germany). The investigation on human cells isolated from peripheral blood was approved by the local ethics board and conform to the Declaration of Helsinki.
Functional in vitro assays
Quantification of cell proliferation was assessed using a BrdU-based Cell Proliferation ELISA assay according to the manufacturer's protocol (Cat. 11 647 229 001, Roche Applied Science, Mannheim, Germany). Cell migration was determined in a fluorescence-blocking version of the Boyden chamber assay. PKA activity was assessed using a PKA Kinase Activity Assay Kit that is based on an ELISA according to the manufacturer's protocol (ab139435, Abcam, Cambridge, UK). Rho activity was measured using an Active Rho Detection Kit based on an immunoblot according to the manufacturer's protocol (8820, Cell Signaling, Danvers, MA, USA). For the evaluation of PKA and RhoA activity, stimulation of the cells was performed after 24 h of serum starvation and the activity was evaluated 15 min after stimulation for the ELISA-based PKA activity assay and 2 h after stimulation for the immunohistochemical detection of SMO at the plasma membrane as well as for the immunoblot-based detection of RhoA activity.
In vitro detection of cytokines and growth factors
For the evaluation of the supernatants of stimulated cells, MSC, fibroblasts, or leukocytes were incubated with test substances for 6 h after 24 h of serum-starvation. After the incubation, cells were washed three times with phosphate-buffered saline and incubated with serum-free medium for another 18 h. The supernatant was then collected and used as a test substance for further in vitro experiments. In vitro cytokine and growth factor release from adventitial fibroblasts was analysed by a human cytokine antibody array according to the manufacturer's instructions (ab133998, Abcam, Cambridge, UK) followed by densometric analysis (ImageJ 1.49v, National Institutes of Health, Bethesda, MD, USA).
Preparation of cellular lysates and immunoblot analysis
Protein extraction and semi-quantitative analysis of protein expression was measured by immunoblotting as previously described.
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Immunoblotting of plasma membrane separations from whole cell lysates in the absence or presence of PDGF-BB was performed 2 h after stimulation using the Mem-PER Plus Membrane Protein Extraction Kit according to the manufacturer's protocol (Thermo Fisher Scientific, Waltham, MA, USA).
Quantitative real-time RT-PCR
Isolation of total RNA and synthesis of cDNA were performed using commercial kits (RNeasy Mini Kit, Qiagen, Hilden, Germany and High Capacity RNA-to-cDNA-Kit, Applied Biosystems, Foster City, CA, USA). Real-time PCR was performed on a Bio-Rad CFX96 Touch TM Real-Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA, USA) using the iQ TM SYBR V R Green Supermix (Bio-Rad Laboratories). Primer sequences, as well as a detailed description of primer validation, are shown in Supplementary material online, Table S1.
Animals and procedures
All procedures concerning animal experiments complied with the Directive 2010/63/EU of the European Parliament as well as with local ethical guidelines and had been approved by the Lower Saxony's institutional committee for animal research (Approval reference number 14/ 1472). All experiments were performed on at least 8-week-old adult male C57BL/6 mice purchased from Charles River (Sulzfeld, Germany). The electric de-endothelialization of the carotid artery and the wire-induced injury of the femoral artery were performed as previously described and as described in the Supplementary material online. 10, 11 Mice were anaesthetized by a singular intraperitoneal injection of 100 mg/kg body weight ketamine hydrochloride (Anesketin, Albrecht, Aulendorf, Germany) and 16 mg/kg body weight xylazine (Rompun V R 2%, Bayer Health Care AG, Leverkusen, Germany) diluted in 0.9% sodium chloride. Adequate anaesthesia was confirmed by the lack of a tail-pinch-induced pain reflex response. Immediately after injury, GDC-0449 (50 mM) or equal amounts of dimethyl sulphoxide (DMSO) as a control were locally applied in 100 mL of the thermosensitive Pluronic 
Statistical analysis
Data were stored and analysed on personal computers using Microsoft Excel 2010 (Microsoft Corporation) and GraphPad Prism 6.01 (GraphPad Software Inc., La Jolla, CA, USA). Data among study groups were analysed using Mann-Whitney U test, Kruskal-Wallis H test followed by multiple comparisons using Dunn's method, or ordinary 1way ANOVA followed by pairwise multiple comparisons using the Tukey method depending on normality, the number of groups, and affecting factors. All data are represented as the mean ± standard error of the mean (SEM). A probability value <0.05 was considered statistically significant for all comparisons.
Results

Neointimal lesion formation is preceded by high adventitial proliferation rates
Following wire-induced vascular injury, a strong inflammatory response of CD45 þ cells to the adventitial layer and a significant increase in the adventitial cellular mass occur before the formation of a neointimal lesion. 12 Immunohistochemical detection of Ki-67 in arteries 7 d after injury revealed that cell proliferation starts mainly within the adventitial layer. The majority of proliferating cells were still localized within the adventitia 14 d after injury (57.08 ± 6.27% in the adventitia vs. 42.92 ± 6.27% in the intima and media, Figure 1A -C). Adventitial proliferation led to adventitial thickening in the course of neointima formation. At 7 d after injury, we performed co-staining of Ki-67 with CD45 as a pan-leukocyte marker, Sca-1 for the detection of MSC, or PDGF receptor-a, vimentin, and periostin as markers for fibroblasts, indicating that the large majority of the proliferating adventitial cells represents neither leukocytes nor MSC but can be referred to as fibroblasts ( Figure 1D and E, see Supplementary material online, Figure S1 ).
Vascular expression of Shh, PTCH1, and SMO is increased following wireinduced injury
In response to vascular injury, the expression of Shh as well as its receptor PTCH1 and downstream target SMO was found to be increased compared with sham-operated arteries, as determined by immunoblotting 14 d after injury (see Supplementary material online, Figure S2A ).
Further immunohistochemical analysis revealed that in injured arteries, the enhanced Shh expression was predominantly located in the medial layer and the developing neointimal lesion, whereas increased PTCH1 Data are presented as means ± SEM; n = 13 mice, more than 6 sections per mouse were analysed; *P < 0.05, ****P < 0.0001 by 1way ANOVA followed by multiple comparisons using the Tukey method. (D and E) Co-staining of Ki-67 (green) with CD45, stem cell antigen-1 (Sca-1), platelet-derived growth factor receptor-a (PDGFR-a), periostin, and vimentin (all red) was performed 7 d after injury and proliferating cells were quantified. Data are presented as means ± SEM; n = 6 mice, more than 6 sections per mouse were analysed. Bars, 100 mm (A, DAPI, a-SMA, Ki-67, merge); 50 mm (A, inlay; D).
and SMO immunoreactivity was most prevalent within the medial and adventitial layer 14 d after injury. In contrast, we detected only a very low expression of PTCH1 and SMO in sham-operated vessels (see Supplementary material online, Figure S2B ). Co-staining of Shh with a-SMA clearly demonstrated high expression levels of Shh in neointimal SMC (see Supplementary material online, Figure S2B ). In vitro, we detected strong expression levels of Shh in human CD45 þ cells and in human coronary artery SMC under baseline conditions. Following stimulation with PDGF-BB, we found a strong upregulation of Shh within SMC but not leukocytes. Notably, PDGF-BB stimulation did also not change the baseline level of Shh protein expression in MSC compared with the respective serum-free controls nor did it induce detectable expression in human adventitial fibroblasts at all (see Supplementary material online, Figure S2C -F).
Inhibition of SMO prevents Shh-and PDGF-BB-induced proliferation and migration of fibroblasts
MSC, adventitial fibroblasts, and SMC were incubated with Shh (3.5 mg/ mL) with or without PDGF-BB (30 ng/mL) in the presence or absence of the specific SMO inhibitor GDC-0449 (10 mM) to evaluate the functional impact of Shh pathway activation in vascular cells. The results from a modified Boyden chamber assay revealed a markedly enhanced migratory response to either Shh or combined Shh-and PDGF-BB-treatment in all cell types. Combined Shh-and PDGF-BB-treatment also significantly induced the proliferation of MSC, fibroblasts, and SMC as determined by BrdU incorporation. Importantly, GDC-0449 exclusively prevented fibroblast proliferation and migration induced by combined Shh-and PDGF-BB-treatment (2.798 ± 0.186-fold vs. 1.732 ± 0.131-fold increased proliferation and 3.261 ± 0.221-fold vs. 2.464 ± 0.158-fold increased migration compared with serum-free control in response to Shh-and PDGF-BB-treatment with or without GDC-0449, respectively, n = 8 and n = 4, ****P < 0.001 and *P < 0.05). Treatment with GDC-0449 neither had an effect on proliferation nor migration in MSC, fibroblasts or SMC, when the respective cells were stimulated with Shh alone (Figure 2A-D) .
Following treatment of the respective vascular cell types with Shh and PDGF-BB, a genetic siRNA-mediated knockdown of SMO confirmed the inhibitory effect on proliferation and migration selectively in fibroblasts (see Supplementary material online, Figure S3 and Figure 2E and F).
To investigate whether Shh can induce a SMC phenotype in fibroblasts, we analysed the expression of a-SMA as well as the more specific SMC marker genes calponin and smooth muscle myosin heavy chain. As determined by qPCR, these SMC marker genes remained unaffected in adventitial fibroblasts in response to treatment with Shh or combined treatment with Shh and PDGF-BB (see Supplementary material online, Figure S4 ).
Shh and PDGF-BB activation of fibroblasts trigger paracrine effects on SMC
Because neointima formation is dependent on the proliferation of medial SMC, we stimulated MSC, fibroblasts, or leukocytes with Shh or Shh and PDGF-BB for 6 h in the presence or absence of GDC-0449. The respective cell types were washed, incubated with serum-free medium for 18 h, and the collected supernatant was used for the induction of SMC proliferation and migration as well as a cytokine array. The supernatant of MSC stimulated with Shh increased the proliferation rates of SMC, and the supernatant of fibroblasts stimulated with Shh and PDGF-BB increased þ murine mesenchymal stem cells (MSC), human aortic adventitial fibroblasts, and human coronary artery smooth muscle cells (HCASMC) were stimulated with either Shh (3.5 mg/mL) or Shh and PDGF-BB (30 ng/mL) in all respective experiments. Proliferation was assessed by a BrdU incorporation ELISA (A þ C) and migration by a modified Boyden chamber assay (B þ D) in the absence or presence of the SMO inhibitor GDC-0449 (10 mM), n = 8 independent experiments for BrdU and n = 4 for Boyden chamber assay. (E and F) MSC, fibroblasts or HCASMC were stimulated and proliferation and migration were assessed after SMO knockdown using siRNA (20 nM), n = 8 independent experiments for BrdU and n = 4 for Boyden chamber assay. *P < 0.05, **P < 0.01, ****P < 0.0001 by one-way ANOVA followed by multiple comparisons using the Tukey method for BrdU and Kruskal-Wallis H test followed by multiple comparisons using the Dunn's method for Boyden chamber assay. All data are presented as means ± SEM. both proliferation and migration of SMC. The addition of GDC-0449 significantly reduced these effects only in fibroblasts (1.724 ± 0.109-fold vs. 1.069 ± 0.165-fold increased proliferation and 2.581 ± 0.451-fold vs. 1.880 ± 0.139-fold increased migration compared to serum-free control in response to Shh-and PDGF-BB-treatment with or without GDC-0449, respectively, n = 8 and n = 4, *P < 0.05). In contrast, the supernatant of GDC-0449 treated MSC stimulated with Shh and PDGF-BB showed a trend toward reduced SMC proliferation, but this effect did not reach statistical significance. With respect to leukocytes, stimulation with Shh and PDGF-BB did not result in increased secretion of paracrine factors affecting SMC proliferation or migration ( Figure 3A and B) .
To identify SMO-dependent regulated cytokines apparent in the supernatant, we used the supernatant isolated from Shh and PDGF-BB stimulated fibroblasts from the same experiment mentioned above in a cytokine antibody array. We found a strong up-regulation of interleukin (IL)-6, IL-8 and the chemokine CXCL-1 in the supernatant of activated fibroblasts, which was attenuated by the addition of the SMO inhibitor GDC-0449 (n = 3, *P < 0.05, Figure 3C and D and see Supplementary material online, Table S2 ).
PDGF-BB induces PKA-dependent SMO trafficking to the plasma membrane of fibroblasts
The SMO-inhibitor GDC-0449 exclusively prevents functional changes of fibroblasts induced by combined stimulation with Shh and PDGF-BB, so that we hypothesized that PDGF-BB might sensitize fibroblasts to Shh stimulation by altering the expression and/or the availability of SMO in the plasma membrane. Indeed, immunohistochemical evaluation and immunoblotting of plasma membrane separations from whole cell lysates revealed an increased translocation of SMO from the cytosol to the plasma membrane in adventitial fibroblasts 2 h after stimulation with PDGF-BB. In contrast, this effect was not observed in SMC or MSC following stimulation with PDGF-BB, as detected by immunohistochemical evaluation ( Figure 4A and B) . Thus, PDGF-BB-induced SMO translocation promotes Shh signalling selectively in fibroblasts and can be specifically inhibited by GDC-0449. The PDGF-BB-induced SMO trafficking to the plasma membrane of fibroblasts was dependent on PKA activity and could be prevented by the addition of KT5720, a specific PKA inhibitor ( Figure 4C) . In response to stimulation with PDGF-BB, PKA activity was strikingly enhanced in fibroblasts and also enhanced in SMC but not in MSC ( Figure 4D ). Consistent with this observation, we detected active PKA within the adventitial layer 14 d after vascular injury, as determined by staining for the catalytic gamma subunit of PKA ( Figure 4E ).
SMO-dependent fibroblast proliferation and migration is RhoA-dependent
To investigate the downstream Shh signalling in adventitial fibroblasts, we performed a qPCR-based pathway profiler analysis. Unexpectedly, we found a significant downregulation of the transcription factor Glidependent target genes PTCH1 and Gli1 itself (probably representing a þ human leukocytes were stimulated with either Shh (3.5 mg/mL) or Shh and PDGF-BB (30 ng/mL) with or without the SMO inhibitor GDC-0449 (10 mM) followed by a 18-h-period of serum-free starvation. The supernatant of the respective cell types was used to stimulate HCASMC. Proliferation of the stimulated HCASMC was assessed by a BrdU incorporation ELISA (A) and migration by a modified Boyden chamber assay (B). Data are presented as means ± SEM, n = 8 independent experiments for BrdU; *P < 0.05, **P < 0.01, by one-way ANOVA followed by multiple comparisons using the Tukey method; n = 4 for Boyden chamber assays, *P < 0.05, by Kruskal-Wallis H test followed by multiple comparisons using Dunn's method. (C and D) Human aortic adventitial fibroblasts were stimulated with Shh (3.5 mg/mL) and PDGF-BB (30 ng/mL) with or without the SMO inhibitor GDC-0449 (10 mM) followed by a period of serum-free starvation. Cytokine and growth factor appearance in the supernatant of the stimulated fibroblasts was determined by a cytokine antibody array (C) followed by densometric analysis with significant differences in CXCL1, IL-6, or IL-8 among other. Data are presented as means ± SEM; n = 3 independent experiments; *P < 0.05 by Kruskal-Wallis H test followed by multiple comparisons using Dunn's method.
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positive feedback regulation) in response to 24 h of Shh and PDGF-BB treatment, which suggests that the signal transduction is not mediated via the canonical pathway but the non-canonical type II Shh-signalling pathway ( Figure 5A ). This finding was confirmed by qPCR of PTCH1 as a target of Gli1 at 4 h after stimulation with Shh and PDGF-BB (see Supplementary material online, Figure S5 ). Because we did not detect a significant up-regulation of other signal transducers of Shh, we focused on potential activators of the non-canonical type II pathway. Indeed, RhoA activity was significantly increased in fibroblasts in response to treatment with Shh and PDGF-BB, as determined by an immunoblotbased assay ( Figure 5B) . Moreover, immunohistochemical detection of active RhoA indicated a marked increase in RhoA activation following vascular injury and showed a predominant localization of active RhoA within the medial and adventitial layer ( Figure 5C , see Supplementary In vitro activity of PKA in response to PDGF-BB (30 ng/mL) was investigated in HCASMC, fibroblasts, and MSC using an ELISA-based PKA activity assay. Data are presented as means ± SEM; n = 3 independent experiments; *P < 0.05, ***P < 0.001 by Kruskal-Wallis H test. (E) Representative immunofluorescence staining for the catalytic gamma subunit of PKA (active PKA, green) and costaining with a-SMA (red) and DAPI (blue) in injured vs. sham-operated murine femoral arteries 14 d after the respective procedure (n = 6 mice; more than three sections per mouse were analysed). Bars, 100 mm.
. Figure S6 ). RhoA activation by the specific Rho activator CN03 rescued the inhibitory effect of GDC-0449 treatment on the proliferation, migration, and paracrine activity of fibroblasts activated with Shh and PDGF-BB, indicating that RhoA mediates these effects downstream of SMO ( Figure 5D -G).
SMO inhibition selectively prevents adventitial cell proliferation and reduces neointima formation
The in vivo effects of fibroblast-selective SMO inhibition on neointimal lesion formation were evaluated after wire-induced injury of the mouse femoral artery and subsequent perivascular application of GDC-0449 in a thermosensitive self-degrading PluronicV R F-127 gel immediately after vascular injury. Here, we found a significant reduction in the total expanse of Ki-67 þ proliferating cells following selective SMO inhibition compared with the vehicle-treated control 14 d after injury (17.00 ± 1.807% vs. 5.50 ± 1.176% Ki-67 þ cells/all cells, n = 6, ***P < 0.001, Figure 6A and B).
The analysis of the different vascular layers revealed that adventitial cells had a similar and significantly reduced proliferative response after GDC-0449 treatment (15.59 ± 0.684% vs. 8.652 ± 1.336%, adventitial Ki-67 þ cells/total adventitial cells, n = 6, **P < 0.01, Figure 6C ). Although we found a clear trend towards an impaired proliferative response in the medial and neointimal layers, the data did not reach statistical significance 14 d after injury ( Figure 6D-E) . Treatment with GDC-0449 strikingly reduced neointimal lesion formation 21 d after wire-induced injury (luminal stenosis 63.47 ± 10.35% vs. 18.09 ± 5.44%, n = 6, **P < 0.01, Figure 6F -H). The medial area size was not affected by SMO inhibition, whereas the neointimal area was significantly reduced following treatment with GDC-0449 ( Figure 6I-K) . In addition, we detected no significant effect of GDC-0449 treatment on proliferation and migration of human coronary artery EC stimulated with Shh or Shh and PDGF-BB ( Figure 7A and B) . Notably, reendothelialization following electrical endothelial injury of the murine carotid artery was not impaired by perivascular application of GDC-0449, as determined by Evan's blue staining and subsequent en face evaluation of the arteries 5 d after electric injury ( Figure 7C) . Furthermore, peripheral blood counts 21 d after injury did not indicate any significant Figure 5 Shh and PDGF-BB treatment activate RhoA but attenuate the activity of Gli1. (A) Human aortic adventitial fibroblasts were stimulated with Shh (3.5 mg/mL) and PDGF-BB (30 ng/mL) in all respective experiments with or without the SMO inhibitor GDC-0449 (10 mM). A quantitative real-time PCRbased pathway profiler assay was performed to investigate the expression of Shh pathway genes. Continuous lines represent the median, broken lines the 95% confidence interval; n = 3 independent experiments; P < 0.05 by Kruskal-Wallis H test followed by multi comparisons using Dunn's method. (B) Fibroblasts were stimulated with or without the SMO inhibitor GDC-0449 (10 mM) and the in vitro activity of RhoA was measured by an immunoblot-based assay. Data are presented as means ± SEM; n = 5 independent experiments; **P < 0.01 by one-way ANOVA followed by multiple comparisons using the Tukey method. (C) Representative immunofluorescence staining for active RhoA (green) and co-staining with a-SMA (red) and DAPI (blue) in injured vs. sham-operated murine femoral arteries 14 d after the respective procedure (n = 6 mice; more than three sections per mouse were analysed). (D and E) Fibroblasts were stimulated with or without the SMO inhibitor GDC-0449 (10 mM) and with or without the RhoA activator CN03 (1 mg/mL) for 24 h. Proliferation was assessed by a BrdU incorporation ELISA (n = 6 independent experiments) and migration by a modified Boyden chamber assay (n = 3 independent experiments). (F and G) Fibroblasts were stimulated with or without the SMO inhibitor GDC-0449 (10 mM) and with or without the RhoA activator CN03 (1 mg/mL) for 6 h and 18 h serum-starved. The respective supernatant was used to stimulate proliferation and migration of human coronary artery smooth muscle cells (HCASMC), as assessed by a BrdU incorporation ELISA (n = 6 independent experiments) and by a modified Boyden chamber assay (n = 3 independent experiments). Data are presented as means ± SEM; *P < 0.05 by Kruskal-Wallis H test followed by multi comparisons using Dunn's method for all Boyden chamber assays. *P < 0.05 by one-way ANOVA followed by multiple comparisons using the Tukey method for all BrdU incorporation ELISA. Bars, 100 mm (C, DAPI, a-SMA, active RhoA, merge); 50 mm (C, inlay). Table S3 ).
Discussion
Many aspects of vascular proliferative diseases remain poorly understood, including the activation of the cells of the adventitial layer after acute vascular injury, the underlying signalling mechanisms and the impact of the adventitia on SMC activation and neointima formation. 13 The data from this study demonstrate that PDGF-BB induces a PKA-dependent translocation of SMO to the plasma membrane of fibroblasts to facilitate Shh signalling. We found that the specific SMO inhibitor GDC-0449 selectively prevents the proliferation and migration of fibroblasts and furthermore impedes the secretion of cytokines from fibroblasts that induce the proliferation and migration of SMC in vitro. The Shh signal transduction pathway downstream of SMO is mainly mediated by activation of RhoA, and is referred to as non-canonical type II signalling. Importantly, inhibition of fibroblast activation by GDC-0449 strongly inhibited adventitial cell proliferation in vivo and the subsequent formation of a neointimal layer. Thus, our data highlight a currently underestimated impact of adventitial fibroblasts on neointima formation and link this mechanism to Shh-dependent signal transduction pathways via SMO and activation of RhoA.
In accordance with previous studies, we observed that the accumulation of inflammatory cells at very early time points after vascular injury was followed by adventitial thickening and adventitial cell proliferation with a large increase in absolute cell numbers. 12 As indicated by costaining of the proliferation marker Ki-67 with CD45, Sca-1 or fibroblast markers, we found that most of the proliferating cells within the adventitia represent fibroblasts and neither leukocytes nor Sca-1 þ MSC.
Although a reliable and specific marker for fibroblasts in immunohistochemistry does not exist, we conclude that the vast majority of these proliferating cells expressing PDGF receptor-a, vimentin, or periostin are fibroblasts. In fact, fibroblasts constitute the major cell fraction of adventitial cells and also show high proliferative rates in many other acute inflammatory diseases, including cardiac remodelling after myocardial infarction. 14 Shh has been crucially implicated in fibroblast activation and function. 4 Following wire-induced injury, we found an enhanced expression of Shh within the media and neointimal lesion, whereas PTCH1 and SMO were up-regulated within cells of the media and surrounding adventitial layer. Conclusively, our in vitro data suggest that Shh is produced by leukocytes, SMC and MSC but not by fibroblasts themselves, even though multiple bands on an immunoblot may be a concern for immunohistochemistry. Therefore, the initial Shh signalling is very likely mediated by early inflammatory cells, which are recruited to the vascular injury site (see Supplementary material online, Figure S7 ). In fact, it is known that Shh is up-regulated and released from inflammation-activated monocytes through activation of the NF-jB signalling pathway. 15 PDGF-BB is also upregulated in the process of neointima formation and we found that PDGF-BB was a strong inducer of Shh expression levels in SMC.
With respect to the cross-talk between the neointima/media and the adventitia, we hypothesize that Shh derived from neointimal and medial cells may contribute to the proliferation of adventitial cells. In response to Shh and PDGF-BB stimulation in vitro, fibroblasts and MSC exhibited increased proliferation and migration rates. Importantly, SMO inhibition with GDC-0449 as well as knock down of SMO using specific siRNAs selectively reduced the proliferation of fibroblasts, since there was no effect on MSC migration and also no significant reduction of MSC proliferation in the multi-variant analysis. Shh induced proliferation and migration of SMC, but in contrast to other studies using the less potent and less specific SMO inhibitor cyclopamine, we did not detect any significant effects of GDC-0449 on SMC proliferation and migration in vitro. 16, 17 Moreover, neither GDC-0449 nor a siRNA-mediated knock down of SMO had a significant effect on SMC function after treatment with Shh/PDGF-BB. Thus, we conclude that the inhibitory effect of GDC-0449 on neointima formation is mainly derived from its strong and selective inhibitory effect on the activation of adventitial fibroblasts with secondary paracrine effects on SMC proliferation and migration. Inflammatory cell-derived growth factors and cytokines have been related to direct activation of resident SMC. In addition, our data now show that the activation of adventitial fibroblasts is a further pathophysiological hallmark of the secretion of cytokines and the sustained inflammatory response contributing to SMC activation. Interestingly, we found that the supernatant isolated from Shh-and PDGF-BB-stimulated fibroblasts, but not leukocytes, induced both the proliferation and migration of SMC. Using the supernatant of activated fibroblasts from the same experiment, we also demonstrated that the stimulation of fibroblasts with Shh and PDGF-BB induces the secretion of IL-6, IL-8, and the chemokine CXCL1. IL-6 is known to drive the inflammatory response to vascular injury and has also been shown to directly induce SMC proliferation and migration.
18-20 IL-8 is a chemoattractant for neutrophils, monocytes and lymphocytes that is upregulated within neointimal lesions and induces SMC proliferation and migration. 21, 22 The chemokine CXCL1 has neutrophil chemoattractant activity, triggers monocyte arrest on activated endothelium, and has also been linked to the process of neointima formation.
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Mechanistically, we found that PDGF-BB leads to activation of PKA and thereby translocation of SMO to the plasma membrane, an effect occurring selectively in fibroblasts. This result suggests that PDGF-BB selectively sensitizes fibroblasts to Shh signalling via SMO, which might explain the selective effect of the SMO-inhibitor GDC-0449 in inhibiting only the activation of fibroblasts in response to Shh and PDGF-BB. Next, we investigated the further downstream Shh signalling using a real-time qPCR-based profiler assay for Shh signalling. Surprisingly, we found a down-regulation of both Gli-1 and PTCH1, which are directly regulated by Gli-1 and thus also indicate activity of the canonical Shh-signalling pathway. In this context, active PKA can inhibit canonical Shh signalling by restraining the transcriptional activity of Gli-1. 25 Therefore, we hypothesized that there was an activation of an alternate pathway and found a strong increase in the activation of RhoA, which is a well-known activator of proliferation and migration in fibroblasts. 26, 27 Interestingly, recent evidence demonstrated a subtle interplay between RhoA and PKA that governs protrusion-retraction cycles in migrating cells. 28 The detected enrichment in both RhoA and PKA activity described in this study may thus explain the enhanced cell proliferation and motility of adventitial fibroblasts. Data on the contribution of fibroblasts to the neointimal cellular mass have been contradictory. 29, 30 One reason might be the finding that in the developing neointimal lesion, myofibroblasts and de-differentiated SMC exert a very similar vascular cell phenotype. 3 Moreover, specific genetic markers of fibroblasts/myofibroblasts that would allow cell-tracking studies are lacking. The observations of high plasticity of different vascular cell types are also supported by recent evidence showing that in the developing atherosclerotic lesions in genetically modified apolipoprotein E -/-mice, >80% of SMC originate from different cell types including macrophages and MSC. 31 Thus, high cell plasticity and trans-differentiation of different cell types, including fibroblasts/myofibroblasts to SMC, seems to occur to a certain extent in the context of vascular proliferative diseases, especially in atherosclerosis.
In an attempt to determine a possible trans-differentiation from fibroblasts to neointimal SMC, we performed in vitro-experiments to track the expression of SMC marker genes after treating fibroblasts with Shh and PDGF-BB but detected no significant increase in any of the specific SMC marker genes. Conclusively, excellent work by Herring et al. 32 recently
showed that following wire-induced injury in mice, the majority of the neointimal cellular mass is in fact derived from SMC of the medial layer. These data were acquired with a dual marker reporter system, and SMC were detected by tamoxifen-induced expression of GFP under the control of the smooth muscle myosin heavy chain promoter. While these results do not rule out a temporary contribution of adventitial fibroblasts to the cellular mass of the developing neointima, they do provide strong evidence that medial SMC are the major source of the definite neointimal cellular mass. Taken together, a direct contribution of a substantial portion of adventitial fibroblasts to the cellular mass of the neointima seems rather unlikely and the expanding adventitial fibroblast population might rather contribute indirectly via a paracrine activation of medial SMC. Neointima formation is also dependent on endothelial recovery, so that we analysed the effects of Shh on EC function in vitro and endothelial recovery. We found no direct effect of Shh with or without application of GDC-0449 on endothelial function in vitro consistent with data from a landmark paper on Shh and angiogenesis by Pola et al. 33 We additionally Figure 7 Local application of GDC-0449 does not influence reendothelialization. (A and B) Human coronary endothelial cells (HCAEC) were stimulated with or without the SMO inhibitor GDC-0449 (10 mM). Proliferation was assessed by a BrdU incorporation ELISA and migration by a modified Boyden chamber assay, n = 6 independent experiments for BrdU and n = 4 independent experiments for Boyden chamber assay; P = n.s. by one-way ANOVA followed by multiple comparisons using the Tukey method (A) or Kruskal-Wallis H test followed by multiple comparisons using Dunn's method (B). Data are presented as means ± SEM. (C) Following electric perivascular injury of the carotid artery, re-endothelialization was assessed 5 d after injury by injection of Evan's Blue and en face analysis. Data are presented as means ± SEM; n = 4-5 mice; P = n.s. by unpaired t-test.
showed that treatment with GDC-0449 does not have detrimental effects on endothelial regeneration 5 d after electric injury of the carotid artery.
In conclusion, our data highlight the so far underestimated role of adventitial fibroblasts in promoting paracrine effects on medial SMC and thus orchestrating the proliferative response to injury. The initial proliferation and expansion of the adventitial fibroblast population and the subsequent release of pro-inflammatory/pro-proliferative cytokines resembles an adventitial 'bioreactor' that further fuels the proliferation and migration of medial SMC and the neointimal narrowing following vascular injury ( Figure 8) . We found that this process is selectively mediated by Shh and PDGF-BB and that inhibition of SMO allows selective inhibition of fibroblasts leading to significant attenuation of neointima formation following vascular injury. Thus, we conclude that further deciphering the role of the adventitial layer will lead to a better understanding of vascular proliferative diseases and will help to optimize current treatment strategies.
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